AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Amikacin is effective against a variety of bacterial infections, including respiratory tract infections, urinary tract infections, bloodstream infections, skin and soft tissue infections, bone and joint infections, and infections in the abdomen.
Mechanism of Action: Amikacin works by inhibiting bacterial protein synthesis, ultimately leading to bacterial cell death. It binds to the bacterial ribosome, interfering with the translation of messenger RNA into proteins essential for bacterial growth and replication.
Serious Side Effects: While amikacin can be an effective antibiotic, it is associated with potential serious side effects, particularly when used for prolonged periods or at high doses. These side effects may include nephrotoxicity (kidney damage), ototoxicity (hearing loss or balance problems), and neuromuscular blockade (muscle weakness or paralysis). Patients receiving amikacin should be closely monitored for signs of these adverse effects.
Nephrotoxicity: Amikacin can cause kidney damage, particularly when used for extended periods or in patients with pre-existing kidney disease. Patients should have their kidney function monitored regularly during treatment with amikacin, and dosage adjustments may be necessary in patients with impaired renal function to prevent nephrotoxicity.
Ototoxicity: Amikacin can cause hearing loss or balance problems, particularly in patients receiving high doses or prolonged treatment. Ototoxicity may be irreversible and can occur even after discontinuation of the medication. Patients should be monitored for signs of hearing loss or balance problems during treatment with amikacin, and dosage adjustments may be necessary to minimize the risk of ototoxicity.
Neuromuscular Blockade: Amikacin can interfere with neuromuscular transmission, leading to muscle weakness or paralysis. This effect may be particularly pronounced in patients with myasthenia gravis or other neuromuscular disorders. Patients receiving amikacin should be closely monitored for signs of neuromuscular blockade, and the medication should be used with caution in patients with pre-existing neuromuscular conditions.
Drug Interactions: Amikacin may interact with other medications, particularly other drugs that are nephrotoxic or ototoxic. Concurrent use of nephrotoxic or ototoxic medications should be avoided or carefully monitored during treatment with amikacin to minimize the risk of adverse effects.
(acemycin, akacin, akamin, akicin, akim, alostil, amexel, amiact, amibac, amicaba, amicacina, amicacina braun, amicacina drawer, amicacina northia, amicacina surar pharma, amicasil, amicilon, amiglyde v, amijeksin, amik, amika, amika-synto, amikabiot, amikacide, amikacin, amikacin - conba pharm, amikacin - harvest pharm, amikacin - tianxin pharm, amikacin - xinhua pharm, amikacin abipharm, amikacin acdima, amikacin aguettant, amikacin amoun, amikacin apex, amikacin b. braun, amikacin bedford, amikacin biomed, amikacin ccpc, amikacin fresenius, amikacin galenika, amikacin galenika ad, amikacin gentle, amikacin hospira, amikacin jw pharmaceutical, amikacin meiji, amikacin norma, amikacin replek farm, amikacin sopharma, amikacin sulfat nichi-iko, amikacin sulfat sawai, amikacin sulfate bayer, amikacin sulfate nikp, amikacin sulfate sandoz, amikacin tai yu, amikacin-tsiteli a, amikacina, amikacina b. braun, amikacina biosano, amikacina chalver, amikacina comerciosa, amikacina disfarmed, amikacina duncan, amikacina ga, amikacina genfar, amikacina klonal, amikacina l.ch., amikacina larjan, amikacina magma, amikacina normon, amikacina richet, amikacina sanderson, amikacina teva, amikacina vitalis, amikacine b. braun, amikacine hospira, amikacine mylan, amikacine mylan enfants et nourrissons, amikagram, amikamek, amikamycin, amikan, amikan-unimed, amikaneu, amikanex, amikarex, amikater, amikavax, amikaver, amikavet, amikaxing suzhou no.6, amikaye, amiketem, amikey, amikin, amikin gsk, amikoside, amikozit, amiksil, amiksins, amimax, aminfec, aminocin, amiosin, amistar, amisul, amitax, amizin, amk-500, amkay, amkeen, amoka, amukin, axcin, bakacin, behkacin, belmaton, bikil, biklin, biodacyna, biodacyna 0.3%, biomikin, biorisan, briklin, brucelin, cadicin, chemacin, cinamak, cinegel, cinmik, dbl amikacin, dramigel, durocin, erkacin, erocin, farcyclin, flexelite, fromentyl, glukamin, glumikin, glybotic, greini, icin, inkacin, ivimicin, kacin, kamina, kancin, karmikin, kasino, kormakin, kupramickin, lanomycin, lemicin, lifermycin, likacin, lukadin, lupamik, macmika, mediamik, merkacin, mezocin, mi li xian, mi ying jie, miacin, micalpha, migracin, mik, mikacin, mikafine, mikaject, mikan, mikasin, mikaven, nekacin, nicpime-am, novacin, novamin, omnikacin, orlobin, park, phil pharmawealth/atlantic amikacin sulfate, pranmika, prutetucin, psudonil, remikin, rikaras, riklinak, romikacin, rovericlin, savox, selemycin, siamik, sikacin, simikan, starkacin, unidikan, unikin, uzix, verdix, vijomikin, xylanal, zamikan)
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Increases |
| genus | Pediococcus | Increases |
| species | Acinetobacter calcoaceticus | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium animalis | Increases |
| species | Bifidobacterium bifidum | Increases |
| species | Bifidobacterium breve | Increases |
| species | Bifidobacterium catenulatum | Increases |
| species | Bifidobacterium longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 11 | 0 | Escherichia coli | species | Decreases |
| 9 | 1 | Klebsiella pneumoniae | species | Decreases |
| 8 | 2 | Klebsiella | genus | Decreases |
| 8 | 0 | Pseudomonas | genus | Decreases |
| 7 | 4 | Escherichia | genus | Decreases |
| 7 | 0 | Kluyvera | genus | Decreases |
| 7 | 0 | Pseudomonas aeruginosa | species | Decreases |
| 6 | 2 | Pseudomonas aeruginosa group | species group | Decreases |
| 5 | 0 | Acinetobacter | genus | Decreases |
| 4 | 1 | Citrobacter | genus | Decreases |
| 4 | 1 | Acinetobacter calcoaceticus/baumannii complex | species group | Decreases |
| 4 | 0 | Enterobacter | genus | Decreases |
| 4 | 0 | Serratia | genus | Decreases |
| 4 | 0 | Staphylococcus | genus | Decreases |
| 4 | 0 | Acinetobacter baumannii | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 1.5 | 1.5 | |
| Acne | 2.8 | 0.6 | 3.67 |
| Addison's Disease (hypocortisolism) | 0.5 | 0.5 | |
| ADHD | 4.3 | 2.4 | 0.79 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 6.4 | 2.3 | 1.78 |
| Allergies | 9.6 | 5.2 | 0.85 |
| Allergy to milk products | 4.5 | 1.5 | 2 |
| Alopecia (Hair Loss) | 1.3 | 0 | 0 |
| Alzheimer's disease | 8.2 | 7.5 | 0.09 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.217 ]